GHRH analogue without the Drug Affinity Complex (DAC) modification. Functionally identical to Modified GRF(1-29). Short-acting GHRH analogue favored by researchers who prefer pulsatile GH release over the sustained "GH bleed" of the DAC version.
CJC-1295 without DAC — sometimes labeled Mod GRF 1-29 — is a shorter-acting synthetic analog of growth hormone releasing hormone (GHRH). Without the Drug Affinity Complex modification, it has a half-life of 30 minutes to a few hours rather than one to two weeks. It is designed to produce a more pulse-like pattern of growth hormone stimulation that more closely resembles natural GHRH activity.
Growth Hormone Pulse Research
The shorter-acting version is designed to be used in a way that mimics natural GHRH pulsation — typically administered at times when natural GH release would normally occur, such as before sleep or exercise. This approach is studied for its ability to amplify GH pulses without producing the flat continuous elevation seen with the DAC version.
Combined Secretagogue Research
CJC-1295 without DAC is frequently studied alongside ghrelin mimetics like ipamorelin. The combination aims to activate both the GHRH and ghrelin pathways simultaneously for a larger, more natural-pattern GH pulse than either compound alone.
Body Composition and Recovery
As with other GH-axis compounds, research interest includes effects on lean mass maintenance, fat metabolism, and tissue recovery, particularly in the context of aging-associated GH decline.
Produces measurable GH release within 30-45 minutes of injection in research subjects.
Shorter duration of action creates a more pulse-like GH pattern compared to the DAC version.
Frequently combined with ipamorelin or GHRP compounds in research protocols.
No large randomized controlled trials specific to this compound have been published.
CJC-1295 without DAC has not been studied in formal large-scale human clinical trials. Research is primarily from small studies and preclinical data. It is not FDA-approved. The appropriate dose, frequency, and long-term safety profile are not established. Because it is often used in combination with other compounds, isolating its individual effects is difficult from available data.
Natural GHRH is released from the hypothalamus in brief pulses that signal the pituitary to release growth hormone. Native GHRH breaks down very quickly — within minutes — so the pulse is sharp and short. CJC-1295 without DAC is a modified GHRH sequence that resists breakdown better than natural GHRH, extending the effective signal to roughly 30 minutes to a few hours. This means that when it is injected around the time of natural GH pulses — before sleep or exercise — it amplifies those pulses rather than creating a continuous flat elevation. It is a different approach from the DAC version, which is more like a constant slow drip of GHRH stimulation over days.
Not FDA-approved, with a safety profile not established in large human trials. The shorter half-life means effects are more transient than with the DAC version, which may be considered favorable from a management standpoint. Considerations around elevated GH and IGF-1 — including blood sugar effects, fluid retention, and long-term cell growth implications — still apply, particularly with frequent repeated use.
Moderate Evidence
This compound has been studied in Phase 1 or Phase 2 human trials. Evidence is encouraging but more large-scale trials are needed.
Published Research Ranges
100–200mcg per injection, typically combined with GHRP; 2–3x daily dosing
Research Context Only: These are ranges reported in published scientific studies for educational reference. They are not dosing recommendations. This is not medical advice. Always consult a qualified healthcare professional.
Sources listed here are from the platform research library. All links open the original publication. No citations are generated by AI.
GHRH Analogues Without Drug Affinity Complex: Short-Acting GH Secretagogues
Journal of Endocrinology • 2006
• DOI: 10.1677/joe.1.06928
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY DISEASE STATE CLINICAL REVIEW: UPDATE ON GROWTH HORMONE STIMULATION TESTING AND PROPOSED REVISED CUT-POINT FOR THE GLUCAGON STIMULATION TEST IN THE DIAGNOSIS OF ADULT GROWTH HORMONE DEFICIENCY
Research Education Only: This profile is for educational purposes only. All information is sourced from published scientific literature. This is not medical advice. Not for human consumption. Consult qualified medical professionals for any health decisions.
We use cookies to enhance your research experience and analyze platform usage. By continuing, you agree to our Cookie Policy.